Renal allograft fibrosis: Biology and therapeutic targets

American Journal of Transplantation

Volumn 15, Issue 4, 2015, Pages 863-886

  Boor, P ^a,b   Floege, J ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b Institute of Molecular BioMedicine   (Slovakia)

Author keywords

basic (laboratory) research science; biomarker; fibrosis; immunosuppressant; kidney transplantation nephrology; molecular biology; pathology histopathology; translational research science

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; CHEMOKINE; CONNECTIVE TISSUE GROWTH FACTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; IMMUNOSUPPRESSIVE AGENT; PLATELET DERIVED GROWTH FACTOR; SCATTER FACTOR; TRANSFORMING GROWTH FACTOR;

CELL POPULATION; CHRONIC KIDNEY DISEASE; DISEASE COURSE; EPIGENETICS; EXTRACELLULAR MATRIX; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY CELL; KIDNEY FIBROSIS; KIDNEY TUBULE CELL; MESENCHYME CELL; MICROCIRCULATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; ULTRASOUND; ADVERSE EFFECTS; ALLOTRANSPLANTATION; FIBROSIS; KIDNEY TRANSPLANTATION;

FIBROSIS; HUMANS; KIDNEY TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 84925338226     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13180     Document Type: Review

References (447)

1. Bohle A, Mackensen-Haen S, von Gise H,. Significance of tubulointerstitial changes in the renal cortex for the excretory function and concentration ability of the kidney: A morphometric contribution. Am J Nephrol 1987; 7: 421-433.
2. Risdon RA, Sloper JC, De Wardener HE,. Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet 1968; 2: 363-366.
3. Cattran DC, Coppo R, Cook HT, et al. The Oxford classification of IgA nephropathy: Rationale, clinicopathological correlations, and classification. Kidney Int 2009; 76: 534-545.
4. Roberts IS, Cook HT, Troyanov S, et al. The Oxford classification of IgA nephropathy: Pathology definitions, correlations, and reproducibility. Kidney Int 2009; 76: 546-556.
5. Solez K, Colvin RB, Racusen LC, et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7: 518-526.
6. Melk A, Schmidt BM, Vongwiwatana A, Rayner DC, Halloran PF,. Increased expression of senescence-associated cell cycle inhibitor p16INK4a in deteriorating renal transplants and diseased native kidney. Am J Transplant 2005; 5: 1375-1382.
7. Dimeny E, Wahlberg J, Larsson E, Fellstrom B,. Can histopathological findings in early renal allograft biopsies identify patients at risk for chronic vascular rejection. Clin Transplant 1995; 9: 79-84.
8. Isoniemi HM, Krogerus L, von Willebrand E, Taskinen E, Ahonen J, Hayry P,. Histopathological findings in well-functioning, long-term renal allografts. Kidney Int 1992; 41: 155-160.
9. El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9: 527-535.
10. Sellares J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012; 12: 388-399.
11. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR,. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-2333.
12. Naesens M, Kuypers DR, De Vusser K, et al. The histology of kidney transplant failure: A long-term follow-up study. Transplantation 2014; 98: 427-435.
13. Naesens M, Kuypers DR, De Vusser K, et al. Chronic histological damage in early indication biopsies is an independent risk factor for late renal allograft failure. Am J Transplant 2013; 13: 86-99.
14. Kasiske BL, Stewart DE, Bista BR, et al. The role of procurement biopsies in acceptance decisions for kidneys retrieved for transplant. Clin J Am Soc Nephrol 2014; 9: 562-571.
15. Azancot MA, Moreso F, Salcedo M, et al. The reproducibility and predictive value on outcome of renal biopsies from expanded criteria donors. Kidney Int 2014; 85: 1161-1168.
16. Colvin RB,. Chronic allograft nephropathy. N Engl J Med 2003; 349: 2288-2290.
17. Cosio FG, Pelletier RP, Falkenhain ME, et al. Impact of acute rejection and early allograft function on renal allograft survival. Transplantation 1997; 63: 1611-1615.
18. Schold JD, Howard RJ, Scicchitano MJ, Meier-Kriesche HU,. The expanded criteria donor policy: An evaluation of program objectives and indirect ramifications. Am J Transplant 2006; 6: 1689-1695.
19. Boor P, Sebekova K, Ostendorf T, Floege J,. Treatment targets in renal fibrosis. Nephrol Dial Transplant 2007; 22: 3391-3407.
20. Decleves AE, Sharma K,. Novel targets of antifibrotic and anti-inflammatory treatment in CKD. Nat Rev Nephrol 2014; 10: 257-267.
21. Tampe D, Zeisberg M,. Potential approaches to reverse or repair renal fibrosis. Nat Rev Nephrol 2014; 10: 226-237.
22. Duffield JS,. Cellular and molecular mechanisms in kidney fibrosis. J Clin Invest 2014; 124: 2299-2306.
23. Meng XM, Nikolic-Paterson DJ, Lan HY,. Inflammatory processes in renal fibrosis. Nat Rev Nephrol 2014; 10: 493-503.
24. Boor P, Floege J,. The renal (myo-) fibroblast: A heterogeneous group of cells. Nephrol Dial Transplant 2012; 27: 3027-3036.
25. Boor P, Ostendorf T, Floege J,. Renal fibrosis: Novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol 2010; 6: 643-656.
26. Anders HJ, Schaefer L,. Beyond tissue injury-damage-associated molecular patterns, toll-like receptors, and inflammasomes also drive regeneration and fibrosis. J Am Soc Nephrol 2014; 25: 1387-1400.
27. Boor P, Konieczny A, Villa L, et al. PDGF-D inhibition by CR002 ameliorates tubulointerstitial fibrosis following experimental glomerulonephritis. Nephrol Dial Transplant 2007; 22: 1323-1331.
28. Viau A, El Karoui, Laouari K, et al. Lipocalin 2 is essential for chronic kidney disease progression in mice and humans. J Clin Invest 2010; 120: 4065-4076.
29. Kurts C, Heymann F, Lukacs-Kornek V, Boor P, Floege J,. Role of T cells and dendritic cells in glomerular immunopathology. Semin Immunopathol 2007; 29: 317-335.
30. Kurts C, Panzer U, Anders HJ, Rees AJ,. The immune system and kidney disease: Basic concepts and clinical implications. Nat Rev Immunol 2013; 13: 738-753.
31. Bernascone I, Janas S, Ikehata M, et al. A transgenic mouse model for uromodulin-associated kidney diseases shows specific tubulo-interstitial damage, urinary concentrating defect and renal failure. Hum Mol Genet 2010; 19: 2998-3010.
32. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K,. Development of monocytes, macrophages, and dendritic cells. Science 327: 656-661.
33. Ricardo SD, van Goor H, Eddy AA,. Macrophage diversity in renal injury and repair. J Clin Invest 2008; 118: 3522-3530.
34. Nishida M, Hamaoka K,. Macrophage phenotype and renal fibrosis in obstructive nephropathy. Nephron Exp Nephrol 2008; 110: e31-e36.
35. Wang Y, Wang Y, Cai Q, et al. By homing to the kidney, activated macrophages potently exacerbate renal injury. Am J Pathol 2008; 172: 1491-1499.
36. Scolari F, Izzi C, Ghiggeri GM,. Uromodulin: From monogenic to multifactorial diseases. Nephrol Dial Transplant 2014. Epub ahead of print.
37. Snelgrove SL, Kausman JY, Lo C, et al. Renal dendritic cells adopt a pro-inflammatory phenotype in obstructive uropathy to activate T cells but do not directly contribute to fibrosis. Am J Pathol 2012; 180: 91-103.
38. Liu J, Krautzberger AM, Sui SH, et al. Cell-specific translational profiling in acute kidney injury. J Clin Invest 2014; 124: 1242-1254.
39. Bondi CD, Manickam N, Lee DY, et al. NAD(P)H oxidase mediates TGF-beta1-induced activation of kidney myofibroblasts. J Am Soc Nephrol 2010; 21: 93-102.
40. Lu J, Cao Q, Zheng D, et al. Discrete functions of M2a and M2c macrophage subsets determine their relative efficacy in treating chronic kidney disease. Kidney Int 2013; 84: 745-755.
41. Hochheiser K, Heuser C, Krause TA, et al. Exclusive CX3CR1 dependence of kidney DCs impacts glomerulonephritis progression. J Clin Invest 2013; 123: 4242-4254.
42. Henderson NC, Mackinnon AC, Farnworth SL, et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 2008; 172: 288-298.
43. Henderson NC, Sethi T,. The regulation of inflammation by galectin-3. Immunol Rev 2009; 230: 160-171.
44. Ma FY, Liu J, Kitching AR, Manthey CL, Nikolic-Paterson DJ,. Targeting renal macrophage accumulation via c-fms kinase reduces tubular apoptosis but fails to modify progressive fibrosis in the obstructed rat kidney. Am J Physiol Renal Physiol 2009; 296: F177-F185.
45. Lin SL, Li B, Rao S, et al. Macrophage Wnt7b is critical for kidney repair and regeneration. Proc Natl Acad Sci USA 2010; 107: 4194-4199.
46. Jin Y, Liu R, Xie J, Xiong H, He JC, Chen N,. Interleukin-10 deficiency aggravates kidney inflammation and fibrosis in the unilateral ureteral obstruction mouse model. Lab Invest 2013; 93: 801-811.
47. Tapmeier TT, Fearn A, Brown K, et al. Pivotal role of CD4+ T cells in renal fibrosis following ureteric obstruction. Kidney Int 2010; 78: 351-362.
48. El-Koraie AF, Baddour NM, Adam AG, El Kashef, El EH, Nahas AM,. Role of stem cell factor and mast cells in the progression of chronic glomerulonephritides. Kidney Int 2001; 60: 167-172.
49. Roberts IS, Brenchley PE,. Mast cells: The forgotten cells of renal fibrosis. J Clin Pathol 2000; 53: 858-862.
50. Kondo S, Kagami S, Kido H, Strutz F, Muller GA, Kuroda Y,. Role of mast cell tryptase in renal interstitial fibrosis. J Am Soc Nephrol 2001; 12: 1668-1676.
51. Papadimitriou JC, Drachenberg CB, Ramos E, Ugarte R, Haririan A,. Mast cell quantitation in renal transplant biopsy specimens as a potential marker for the cumulative burden of tissue injury. Transplant Proc 2013; 45: 1469-1471.
52. Kanamaru Y, Scandiuzzi L, Essig M, et al. Mast cell-mediated remodeling and fibrinolytic activity protect against fatal glomerulonephritis. J Immunol 2006; 176: 5607-5615.
53. Miyazawa S, Hotta O, Doi N, Natori Y, Nishikawa K, Natori Y,. Role of mast cells in the development of renal fibrosis: Use of mast cell-deficient rats. Kidney Int 2004; 65: 2228-2237.
54. Hochegger K, Siebenhaar F, Vielhauer V, et al. Role of mast cells in experimental anti-glomerular basement membrane glomerulonephritis. Eur J Immunol 2005; 35: 3074-3082.
55. Kim DH, Moon SO, Jung YJ, et al. Mast cells decrease renal fibrosis in unilateral ureteral obstruction. Kidney Int 2009; 75: 1031-1038.
56. Beghdadi W, Madjene LC, Claver J, et al. Mast cell chymase protects against renal fibrosis in murine unilateral ureteral obstruction. Kidney Int 2013; 84: 317-326.
57. Timoshanko JR, Kitching R, Semple TJ, Tipping PG, Holdsworth SR,. A pathogenetic role for mast cells in experimental crescentic glomerulonephritis. J Am Soc Nephrol 2006; 17: 150-159.
58. Fan YY, Nishiyama A, Fujisawa Y, et al. Contribution of chymase-dependent angiotensin II formation to the progression of tubulointerstitial fibrosis in obstructed kidneys in hamsters. J Pharmacol Sci 2009; 111: 82-90.
59. Madjene LC, Pons M, Danelli L, Claver J, Ali L, Madera-Salcedo IK, et al. Mast cells in renal inflammation and fibrosis: Lessons learnt from animal studies. Mol Immunol 2015; 63: 86-93.
60. Sakai N, Wada T, Yokoyama H, et al. Secondary lymphoid tissue chemokine (SLC/CCL21)/CCR7 signaling regulates fibrocytes in renal fibrosis. Proc Natl Acad Sci USA 2006; 103: 14098-14103.
61. Pilling D, Fan T, Huang D, Kaul B, Gomer RH,. Identification of markers that distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts. PLoS ONE 2009; 4: e7475.
62. Reich B, Schmidbauer K, Rodriguez Gomez, et al. Fibrocytes develop outside the kidney but contribute to renal fibrosis in a mouse model. Kidney Int 2013; 84: 78-89.
63. Niedermeier M, Reich B, Rodriguez Gomez, et al. CD4+ T cells control the differentiation of Gr1+ monocytes into fibrocytes. Proc Natl Acad Sci USA 2009; 106: 17892-17897.
64. Lin SL, Castano AP, Nowlin BT, Lupher ML, Jr., Duffield JS,. Bone marrow Ly6Chigh monocytes are selectively recruited to injured kidney and differentiate into functionally distinct populations. J Immunol 2009; 183: 6733-6743.
65. Lin SL, Kisseleva T, Brenner DA, Duffield JS,. Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am J Pathol 2008; 173: 1617-1627.
66. Roufosse C, Bou-Gharios G, Prodromidi E, et al. Bone marrow-derived cells do not contribute significantly to collagen I synthesis in a murine model of renal fibrosis. J Am Soc Nephrol 2006; 17: 775-782.
67. Lebleu VS, Taduri G, O'Connell J, et al. Origin and function of myofibroblasts in kidney fibrosis. Nat Med 2013; 19: 1047-1053.
68. Broekema M, Harmsen MC, van Luyn MJ, et al. Bone marrow-derived myofibroblasts contribute to the renal interstitial myofibroblast population and produce procollagen I after ischemia/reperfusion in rats. J Am Soc Nephrol 2007; 18: 165-175.
69. Sakamoto I, Ito Y, Mizuno M, et al. Lymphatic vessels develop during tubulointerstitial fibrosis. Kidney Int 2009; 75: 828-838.
70. Matsui K, Nagy-Bojarsky K, Laakkonen P, et al. Lymphatic microvessels in the rat remnant kidney model of renal fibrosis: Aminopeptidase p and podoplanin are discriminatory markers for endothelial cells of blood and lymphatic vessels. J Am Soc Nephrol 2003; 14: 1981-1989.
71. Kerjaschki D, Regele HM, Moosberger I, et al. Lymphatic neoangiogenesis in human kidney transplants is associated with immunologically active lymphocytic infiltrates. J Am Soc Nephrol 2004; 15: 603-612.
72. Stuht S, Gwinner W, Franz I, et al. Lymphatic neoangiogenesis in human renal allografts: Results from sequential protocol biopsies. Am J Transplant 2007; 7: 377-384.
73. Kunjachan S, Pola R, Gremse F, et al. Passive versus active tumor targeting using RGD- and NGR-modified polymeric nanomedicines. Nano Lett 2014; 14: 972-981.
74. Zhang T, Guan G, Liu G, et al. Disturbance of lymph circulation develops renal fibrosis in rats with or without contralateral nephrectomy. Nephrology (Carlton) 2008; 13: 128-138.
75. Zhang T, Liu G, Sun M, Guan G, Chen B, Li X,. Functional, histological and biochemical consequences of renal lymph disorder in mononephrectomized rats. J Nephrol 2009; 22: 109-116.
76. Lee AS, Lee JE, Jung YJ, et al. Vascular endothelial growth factor-C and -D are involved in lymphangiogenesis in mouse unilateral ureteral obstruction. Kidney Int 2013; 83: 50-62.
77. Ehling J, Theek B, Gremse F, et al. Micro-CT imaging of tumor angiogenesis: Quantitative measures describing micromorphology and vascularization. Am J Pathol 2014; 184: 431-441.
78. Cao R, Bjorndahl MA, Religa P, et al. PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell 2004; 6: 333-345.
79. Cao Y,. Direct role of PDGF-BB in lymphangiogenesis and lymphatic metastasis. Cell Cycle 2005; 4: 228-230.
80. Noris M, Remuzzi G,. Overview of complement activation and regulation. Semin Nephrol 2013; 33: 479-492.
81. Cravedi P, Heeger PS,. Complement as a multifaceted modulator of kidney transplant injury. J Clin Invest 2014; 124: 2348-2354.
82. Potla U, Ni J, Vadaparampil J, et al. Podocyte-specific RAP1GAP expression contributes to focal segmental glomerulosclerosis-associated glomerular injury. J Clin Invest 2014; 124: 1757-1769.
83. Mack M, Yanagita M,. Origin of myofibroblasts and cellular events triggering fibrosis. Kidney Int 2014.
84. Rangan GK, Pippin JW, Coombes JD, Couser WG,. C5b-9 does not mediate chronic tubulointerstitial disease in the absence of proteinuria. Kidney Int 2005; 67: 492-503.
85. Rangan GK, Pippin JW, Couser WG,. C5b-9 regulates peritubular myofibroblast accumulation in experimental focal segmental glomerulosclerosis. Kidney Int 2004; 66: 1838-1848.
86. Boor P, Konieczny A, Villa L, et al. Complement C5 mediates experimental tubulointerstitial fibrosis. J Am Soc Nephrol 2007; 18: 1508-1515.
87. Pan H, Shen Z, Mukhopadhyay P, et al. Anaphylatoxin C5a contributes to the pathogenesis of cisplatin-induced nephrotoxicity. Am J Physiol Renal Physiol 2009; 296: F496-F504.
88. Okamura DM, Bahrami NM, Ren S, et al. Cysteamine modulates oxidative stress and blocks myofibroblast activity in CKD. J Am Soc Nephrol 2014; 25: 43-54.
89. Li Q, Peng Q, Xing G, et al. Deficiency of C5aR prolongs renal allograft survival. J Am Soc Nephrol 2010; 21: 1344-1353.
90. Bollee G, Flamant M, Schordan S, et al. Epidermal growth factor receptor promotes glomerular injury and renal failure in rapidly progressive crescentic glomerulonephritis. Nat Med 2011; 17: 1242-1250.
91. Eremina V, Baelde HJ, Quaggin SE,. Role of the VEGF-A signaling pathway in the glomerulus: Evidence for crosstalk between components of the glomerular filtration barrier. Nephron Physiol 2007; 106: p32-p37.
92. Eremina V, Cui S, Gerber H, et al. Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival. J Am Soc Nephrol 2006; 17: 724-735.
93. Eremina V, Sood M, Haigh J, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003; 111: 707-716.
94. van Roeyen CR, Eitner F, Boor P, et al. Induction of progressive glomerulonephritis by podocyte-specific overexpression of platelet-derived growth factor-D. Kidney Int 2011; 80: 1292-1305.
95. Hakroush S, Cebulla A, Schaldecker T, Behr D, Mundel P, Weins A,. Extensive podocyte loss triggers a rapid parietal epithelial cell response. J Am Soc Nephrol 2014; 25: 927-938.
96. Byron A, Randles MJ, Humphries JD, et al. Glomerular cell cross-talk influences composition and assembly of extracellular matrix. J Am Soc Nephrol 2014; 25: 953-966.
97. Hasegawa K, Wakino S, Simic P, et al. Renal tubular Sirt1 attenuates diabetic albuminuria by epigenetically suppressing Claudin-1 overexpression in podocytes. Nat Med 2013; 19: 1496-1504.
98. Berger K, Schulte K, Boor P, et al. The regenerative potential of parietal epithelial cells in adult mice. J Am Soc Nephrol 2014; 25: 693-705.
99. Smeets B, Moeller MJ,. Parietal epithelial cells and podocytes in glomerular diseases. Semin Nephrol 2012; 32: 357-367.
100. D'Agati VD, Kaskel FJ, Falk RJ,. Focal segmental glomerulosclerosis. N Engl J Med 2011; 365: 2398-2411.
101. Godel M, Hartleben B, Herbach N, et al. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest 2011; 121: 2197-2209.
102. Inoki K, Mori H, Wang J, et al. MTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J Clin Invest 2011; 121: 2181-2196.
103. Fukuda A, Chowdhury MA, Venkatareddy MP, et al. Growth-dependent podocyte failure causes glomerulosclerosis. J Am Soc Nephrol 2012; 23: 1351-1363.
104. Fukuda A, Wickman LT, Venkatareddy MP, et al. Angiotensin II-dependent persistent podocyte loss from destabilized glomeruli causes progression of end stage kidney disease. Kidney Int 2012; 81: 40-55.
105. Gebeshuber CA, Kornauth C, Dong L, et al. Focal segmental glomerulosclerosis is induced by microRNA-193a and its downregulation of WT1. Nat Med 2013; 19: 481-487.
106. Hayashi K, Sasamura H, Nakamura M, et al. KLF4-dependent epigenetic remodeling modulates podocyte phenotypes and attenuates proteinuria. J Clin Invest 2014; 124: 2523-2537.
107. Rutkowski JM, Wang ZV, Park AS, et al. Adiponectin promotes functional recovery after podocyte ablation. J Am Soc Nephrol 2013; 24: 268-282.
108. Zhu L, Jiang R, Aoudjit L, Jones N, Takano T,. Activation of RhoA in podocytes induces focal segmental glomerulosclerosis. J Am Soc Nephrol 2011; 22: 1621-1630.
109. Schulte K, Berger K, Boor P, et al. Origin of parietal podocytes in atubular glomeruli mapped by lineage tracing. J Am Soc Nephrol 2014; 25: 129-141.
110. Hackl MJ, Burford JL, Villanueva K, et al. Tracking the fate of glomerular epithelial cells in vivo using serial multiphoton imaging in new mouse models with fluorescent lineage tags. Nat Med 2013; 19: 1661-1666.
111. Matsusaka T, Kobayashi K, Kon V, Pastan I, Fogo AB, Ichikawa I,. Glomerular sclerosis is prevented during urinary tract obstruction due to podocyte protection. Am J Physiol Renal Physiol 2011; 300: F792-F800.
112. Kriz W, Lemley KV,. A potential role for mechanical forces in the detachment of podocytes and the progression of CKD. J Am Soc Nephrol 2014.
113. Daehn I, Casalena G, Zhang T, et al. Endothelial mitochondrial oxidative stress determines podocyte depletion in segmental glomerulosclerosis. J Clin Invest 2014; 124: 1608-1621.
114. Sun YB, Qu X, Zhang X, Caruana G, Bertram JF, Li J,. Glomerular endothelial cell injury and damage precedes that of podocytes in adriamycin-induced nephropathy. PLoS ONE 2013; 8: e55027.
115. Devi S, Li A, Westhorpe CL, et al. Multiphoton imaging reveals a new leukocyte recruitment paradigm in the glomerulus. Nat Med 2013; 19: 107-112.
116. Schlondorff D, Banas B,. The mesangial cell revisited: No cell is an island. J Am Soc Nephrol 2009; 20: 1179-1187.
117. Ning L, Kurihara H, de Vega S, et al. Laminin alpha1 regulates age-related mesangial cell proliferation and mesangial matrix accumulation through the TGF-beta pathway. Am J Pathol 2014; 184: 1683-1694.
118. Starke C, Betz H, Hickmann L, et al. Renin lineage cells repopulate the glomerular mesangium after injury. J Am Soc Nephrol 2014.
119. Moeller MJ, Smeets B,. Novel target in the treatment of RPGN: The activated parietal cell. Nephrol Dial Transplant 2013; 28: 489-492.
120. Shankland SJ, Smeets B, Pippin JW, Moeller MJ,. The emergence of the glomerular parietal epithelial cell. Nat Rev Nephrol 2014; 10: 158-173.
121. Sicking EM, Fuss A, Uhlig S, et al. Subtotal ablation of parietal epithelial cells induces crescent formation. J Am Soc Nephrol 2012; 23: 629-640.
122. Smeets B, Uhlig S, Fuss A, et al. Tracing the origin of glomerular extracapillary lesions from parietal epithelial cells. J Am Soc Nephrol 2009; 20: 2604-2615.
123. Smeets B, Kuppe C, Sicking EM, et al. Parietal epithelial cells participate in the formation of sclerotic lesions in focal segmental glomerulosclerosis. J Am Soc Nephrol 2011; 22: 1262-1274.
124. Smeets B, Stucker F, Wetzels J, et al. Detection of activated parietal epithelial cells on the glomerular tuft distinguishes early focal segmental glomerulosclerosis from minimal change disease. Am J Pathol 2014.
125. Kriz W, LeHir M,. Pathways to nephron loss starting from glomerular diseases-Insights from animal models. Kidney Int 2005; 67: 404-419.
126. Guo JK, Marlier A, Shi H, et al. Increased tubular proliferation as an adaptive response to glomerular albuminuria. J Am Soc Nephrol 2012; 23: 429-437.
127. Tasanarong A, Kongkham S, Khositseth S,. Dual inhibiting senescence and epithelial-to-mesenchymal transition by erythropoietin preserve tubular epithelial cell regeneration and ameliorate renal fibrosis in unilateral ureteral obstruction. Bio Med Res Int 2013; 2013: 308130.
128. Yang H, Fogo AB,. Cell senescence in the aging kidney. J Am Soc Nephrol 2010; 21: 1436-1439.
129. Chevalier RL,. Obstructive nephropathy: Towards biomarker discovery and gene therapy. Nat Clin Pract Nephrol 2006; 2: 157-168.
130. Docherty NG, O'Sullivan OE, Healy DA, Fitzpatrick JM, Watson RW,. Evidence that inhibition of tubular cell apoptosis protects against renal damage and development of fibrosis following ureteric obstruction. Am J Physiol Renal Physiol 2006; 290: F4-13.
131. Li L, Zepeda-Orozco D, Black R, Lin F,. Autophagy is a component of epithelial cell fate in obstructive uropathy. Am J Pathol 2010; 176: 1767-1778.
132. Kume S, Uzu T, Horiike K, et al. Calorie restriction enhances cell adaptation to hypoxia through Sirt1-dependent mitochondrial autophagy in mouse aged kidney. J Clin Invest 2010; 120: 1043-1055.
133. Cybulsky AV,. Endoplasmic reticulum stress in proteinuric kidney disease. Kidney Int 2010; 77: 187-193.
134. Inagi R,. Endoplasmic reticulum stress in the kidney as a novel mediator of kidney injury. Nephron Exp Nephrol 2009; 112: e1-e9.
135. Gozuacik D, Bialik S, Raveh T, et al. DAP-kinase is a mediator of endoplasmic reticulum stress-induced caspase activation and autophagic cell death. Cell Death Differ 2008; 15: 1875-1886.
136. Periyasamy-Thandavan S, Jiang M, Schoenlein P, Dong Z,. Autophagy: molecular machinery, regulation, and implications for renal pathophysiology. Am J Physiol Renal Physiol 2009; 297: F244-F256.
137. Yang L, Besschetnova TY, Brooks CR, Shah JV, Bonventre JV,. Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med 2010; 16: 535-543.
138. Boor P, Celec P, Martin IV, et al. The peroxisome proliferator-activated receptor-alpha agonist, BAY PP1, attenuates renal fibrosis in rats. Kidney Int 2011; 80: 1182-1197.
139. Ruan XZ, Varghese Z, Moorhead JF,. An update on the lipid nephrotoxicity hypothesis. Nat Rev Nephrol 2009; 5: 713-721.
140. Wu J, Chen L, Zhang D, et al. Peroxisome proliferator-activated receptors and renal diseases. Front Biosci 2009; 14: 995-1009.
141. Li S, Mariappan N, Megyesi J, et al. Proximal tubule PPARalpha attenuates renal fibrosis and inflammation caused by unilateral ureteral obstruction. Am J Physiol Renal Physiol 2013; 305: F618-F627.
142. Toblli JE, Ferrini MG, Cao G, Vernet D, Angerosa M, Gonzalez-Cadavid NF,. Antifibrotic effects of pioglitazone on the kidney in a rat model of type 2 diabetes mellitus. Nephrol Dial Transplant 2009; 24: 2384-2391.
143. Menke J, Iwata Y, Rabacal WA, et al. CSF-1 signals directly to renal tubular epithelial cells to mediate repair in mice. J Clin Invest 2009; 119: 2330-2342.
144. Bielesz B, Sirin Y, Si H, et al. Epithelial Notch signaling regulates interstitial fibrosis development in the kidneys of mice and humans. J Clin Invest 2010; 120: 4040-4054.
145. Humphreys BD, Xu F, Sabbisetti V, et al. Chronic epithelial kidney injury molecule-1 expression causes murine kidney fibrosis. J Clin Invest 2013; 123: 4023-4035.
146. Hao S, He W, Li Y, et al. Targeted inhibition of beta-catenin/CBP signaling ameliorates renal interstitial fibrosis. J Am Soc Nephrol 2011; 22: 1642-1653.
147. Chen J, Chen JK, Nagai K, et al. EGFR signaling promotes TGFbeta-dependent renal fibrosis. J Am Soc Nephrol 2012; 23: 215-224.
148. Liu N, Guo JK, Pang M, et al. Genetic or pharmacologic blockade of EGFR inhibits renal fibrosis. J Am Soc Nephrol 2012; 23: 854-867.
149. Anders HJ,. Immune system modulation of kidney regeneration-Mechanisms and implications. Nat Rev Nephrol 2014; 10: 347-358.
150. Boor P, Floege J,. Chronic kidney disease growth factors in renal fibrosis. Clin Exp Pharmacol Physiol 2011; 38: 391-400.
151. Borges FT, Melo SA, Ozdemir BC, et al. TGF-beta1-containing exosomes from injured epithelial cells activate fibroblasts to initiate tissue regenerative responses and fibrosis. J Am Soc Nephrol 2013; 24: 385-392.
152. Zhou D, Li Y, Zhou L, et al. Sonic hedgehog is a novel tubule-derived growth factor for interstitial fibroblasts after kidney injury. J Am Soc Nephrol 2014; 25: 2187-2200.
153. Ding H, Zhou D, Hao S, et al. Sonic hedgehog signaling mediates epithelial-mesenchymal communication and promotes renal fibrosis. J Am Soc Nephrol 2012; 23: 801-813.
154. Fabian SL, Penchev RR, St-Jacques B, et al. Hedgehog-Gli pathway activation during kidney fibrosis. Am J Pathol 2012; 180: 1441-1453.
155. Fujiu K, Manabe I, Nagai R,. Renal collecting duct epithelial cells regulate inflammation in tubulointerstitial damage in mice. J Clin Invest 2011; 121: 3425-3441.
156. Grgic I, Campanholle G, Bijol V, et al. Targeted proximal tubule injury triggers interstitial fibrosis and glomerulosclerosis. Kidney Int 2012; 82: 172-183.
157. Keller BJ, Martini S, Sedor JR, Kretzler M,. A systems view of genetics in chronic kidney disease. Kidney Int 2012; 81: 14-21.
158. Jin Y, Ratnam K, Chuang PY, et al. A systems approach identifies HIPK2 as a key regulator of kidney fibrosis. Nat Med 2012; 18: 580-588.
159. Kottgen A, Pattaro C, Boger CA, et al. New loci associated with kidney function and chronic kidney disease. Nat Genet 2010; 42: 376-384.
160. Kopp JB, Smith MW, Nelson GW, et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008; 40: 1175-1184.
161. Chambers JC, Zhang W, Lord GM, et al. Genetic loci influencing kidney function and chronic kidney disease. Nat Genet 2010; 42: 373-375.
162. Suzuki N, Kunishima S, Ikejiri M, et al. Establishment of mouse model of MYH9 disorders: Heterozygous R702C mutation provokes macrothrombocytopenia with leukocyte inclusion bodies, renal glomerulosclerosis and hearing disability. PLoS ONE 2013; 8: e71187.
163. Johnstone DB, Ikizler O, Zhang J, Holzman LB,. Background strain and the differential susceptibility of podocyte-specific deletion of Myh9 on murine models of experimental glomerulosclerosis and HIV nephropathy. PLoS ONE 2013; 8: e67839.
164. Johnstone DB, Zhang J, George B, et al. Podocyte-specific deletion of Myh9 encoding nonmuscle myosin heavy chain 2A predisposes mice to glomerulopathy. Mol Cell Biol 2011; 31: 2162-2170.
165. Trudu M, Janas S, Lanzani C, et al. Common noncoding UMOD gene variants induce salt-sensitive hypertension and kidney damage by increasing uromodulin expression. Nat Med 2013; 19: 1655-1660.
166. Asada N, Takase M, Nakamura J, et al. Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice. J Clin Invest 2011; 121: 3981-3990.
167. Souma T, Yamazaki S, Moriguchi T, et al. Plasticity of renal erythropoietin-producing cells governs fibrosis. J Am Soc Nephrol 2013; 24: 1599-1616.
168. Kramann R, Humphreys BD,. Kidney pericytes: Roles in regeneration and fibrosis. Semin Nephrol 2014; 34: 374-383.
169. Grgic I, Krautzberger AM, Hofmeister A, et al. Translational profiles of medullary myofibroblasts during kidney fibrosis. J Am Soc Nephrol 2014; 25: 1979-1990.
170. Lebleu VS, Teng Y, O'Connell JT, et al. Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis. Nat Med 2013; 19: 227-231.
171. Das A, Tanigawa S, Karner CM, et al. Stromal-epithelial crosstalk regulates kidney progenitor cell differentiation. Nat Cell Biol 2013; 15: 1035-1044.
172. Kriz W, Kaissling B, Le Hir M,. Epithelial-mesenchymal transition (EMT) in kidney fibrosis: Fact or fantasy. J Clin Invest 2011; 121: 468-474.
173. Quaggin SE, Kapus A,. Scar wars: Mapping the fate of epithelial-mesenchymal-myofibroblast transition. Kidney Int 2011; 80: 41-50.
174. Grgic I, Duffield JS, Humphreys BD,. The origin of interstitial myofibroblasts in chronic kidney disease. Pediatr Nephrol 2012; 27: 183-193.
175. Liu Y,. New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol 2010; 21: 212-222.
176. Zeisberg M, Duffield JS,. Resolved: EMT produces fibroblasts in the kidney. J Am Soc Nephrol 2010; 21: 1247-1253.
177. Yang J, Lin SC, Chen G, et al. Adiponectin promotes monocyte-to-fibroblast transition in renal fibrosis. J Am Soc Nephrol 2013; 24: 1644-1659.
178. Chen G, Lin SC, Chen J, et al. CXCL16 recruits bone marrow-derived fibroblast precursors in renal fibrosis. J Am Soc Nephrol 2011; 22: 1876-1886.
179. Smeets B, Boor P, Dijkman H, et al. Proximal tubular cells contain a phenotypically distinct, scattered cell population involved in tubular regeneration. J Pathol 2013; 229: 645-659.
180. Zeisberg EM, Potenta SE, Sugimoto H, Zeisberg M, Kalluri R,. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol 2008; 19: 2282-2287.
181. Li J, Qu X, Bertram JF,. Endothelial-myofibroblast transition contributes to the early development of diabetic renal interstitial fibrosis in streptozotocin-induced diabetic mice. Am J Pathol 2009; 175: 1380-1388.
182. Humphreys BD, Lin SL, Kobayashi A, et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol 2010; 176: 85-97.
183. DiRocco DP, Kobayashi A, Taketo MM, McMahon AP, Humphreys BD,. Wnt4/beta-catenin signaling in medullary kidney myofibroblasts. J Am Soc Nephrol 2013; 24: 1399-1412.
184. Ren S, Johnson BG, Kida Y, et al. LRP-6 is a coreceptor for multiple fibrogenic signaling pathways in pericytes and myofibroblasts that are inhibited by DKK-1. Proc Natl Acad Sci USA 2013; 110: 1440-1445.
185. Nlandu Khodo, Dizin S, Sossauer E, et al. NADPH-oxidase 4 protects against kidney fibrosis during chronic renal injury. J Am Soc Nephrol 2012; 23: (12):.
186. Henderson NC, Arnold TD, Katamura Y, et al. Targeting of alphav integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med 2013; 19: 1617-1624.
187. Jiang L, Xu L, Mao J, et al. Rheb/mTORC1 signaling promotes kidney fibroblast activation and fibrosis. J Am Soc Nephrol 2013; 24: 1114-1126.
188. Boor P,. EP4: A new piece in the fibrotic puzzle. Kidney Int 2012; 82: 132-135.
189. Nakagawa N, Yuhki K, Kawabe J, et al. The intrinsic prostaglandin E2-EP4 system of the renal tubular epithelium limits the development of tubulointerstitial fibrosis in mice. Kidney Int 2012; 82: 158-171.
190. Nasu T, Kinomura M, Tanabe K, et al. Sustained-release prostacyclin analog ONO-1301 ameliorates tubulointerstitial alterations in a mouse obstructive nephropathy model. Am J Physiol Renal Physiol 2012; 302: F1616-F1629.
191. Borgeson E, Docherty NG, Murphy M, et al. Lipoxin A(4) and benzo-lipoxin A(4) attenuate experimental renal fibrosis. FASEB J 2011; 25: 2967-2979.
192. Brennan EP, Nolan KA, Borgeson E, et al. Lipoxins attenuate renal fibrosis by inducing let-7c and suppressing TGFbetaR1. J Am Soc Nephrol 2013; 24: 627-637.
193. Tanaka T, Nangaku M,. Angiogenesis and hypoxia in the kidney. Nat Rev Nephrol 2013; 9: 211-222.
194. Kida Y, Tchao BN, Yamaguchi I,. Peritubular capillary rarefaction: A new therapeutic target in chronic kidney disease. Pediatr Nephrol 2014; 29: 333-342.
195. Long DA, Norman JT, Fine LG,. Restoring the renal microvasculature to treat chronic kidney disease. Nat Rev Nephrol 2012; 8: 244-250.
196. Guerrot D, Dussaule JC, Kavvadas P, Boffa JJ, Chadjichristos CE, Chatziantoniou C,. Progression of renal fibrosis: The underestimated role of endothelial alterations. Fibrogenesis Tissue Repair 2012; 5 (Suppl 1): S15.
197. Chade AR,. Renovascular disease, microcirculation, and the progression of renal injury: Role of angiogenesis. Am J Physiol Regul Integr Comp Physiol 2011; 300: R783-R790.
198. Maric-Bilkan C, Flynn ER, Chade AR,. Microvascular disease precedes the decline in renal function in the streptozotocin-induced diabetic rat. Am J Physiol Renal Physiol 2012; 302: F308-F315.
199. Kramann R, Tanaka M, Humphreys BD,. Fluorescence microangiography for quantitative assessment of peritubular capillary changes after AKI in mice. J Am Soc Nephrol 2014; 25: 1924-1931.
200. Higgins DF, Kimura K, Bernhardt WM, et al. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest 2007; 117: 3810-3820.
201. Kimura K, Iwano M, Higgins DF, et al. Stable expression of HIF-1alpha in tubular epithelial cells promotes interstitial fibrosis. Am J Physiol Renal Physiol 2008; 295: F1023-F1029.
202. Higgins DF, Kimura K, Iwano M, Haase VH,. Hypoxia-inducible factor signaling in the development of tissue fibrosis. Cell Cycle 2008; 7: 1128-1132.
203. Tanaka T, Yamaguchi J, Higashijima Y, Nangaku M,. Indoxyl sulfate signals for rapid mRNA stabilization of Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 2 (CITED2) and suppresses the expression of hypoxia-inducible genes in experimental CKD and uremia. Faseb J 2013; 27: 4059-4075.
204. Hakroush S, Moeller MJ, Theilig F, et al. Effects of increased renal tubular vascular endothelial growth factor (VEGF) on fibrosis, cyst formation, and glomerular disease. Am J Pathol 2009; 175: 1883-1895.
205. Schirutschke H, Vogelbacher R, Stief A, Parmentier S, Daniel C, Hugo C,. Injured kidney endothelium is only marginally repopulated by cells of extrarenal origin. Am J Physiol Renal Physiol 2013; 305: F1042-F1052.
206. Grutzmacher C, Park S, Zhao Y, Morrison ME, Sheibani N, Sorenson CM,. Aberrant production of extracellular matrix proteins and dysfunction in kidney endothelial cells with a short duration of diabetes. Am J Physiol Renal Physiol 2013; 304: F19-F30.
207. Lin SL, Chang FC, Schrimpf C, et al. Targeting endothelium-pericyte cross talk by inhibiting VEGF receptor signaling attenuates kidney microvascular rarefaction and fibrosis. Am J Pathol 2011; 178: 911-923.
208. Kida Y, Ieronimakis N, Schrimpf C, Reyes M, Duffield JS,. EphrinB2 reverse signaling protects against capillary rarefaction and fibrosis after kidney injury. J Am Soc Nephrol 2013; 24: 559-572.
209. Wilkinson L, Gilbert T, Sipos A, et al. Loss of renal microvascular integrity in postnatal Crim1 hypomorphic transgenic mice. Kidney Int 2009; 76: 1161-1171.
210. Lee D, Shenoy S, Nigatu Y, Plotkin M,. Id proteins regulate capillary repair and perivascular cell proliferation following ischemia-reperfusion injury. PLoS ONE 2014; 9: e88417.
211. Bijkerk R, van Solingen C, de Boer HC, et al. Hematopoietic microRNA-126 protects against renal ischemia/reperfusion injury by promoting vascular integrity. J Am Soc Nephrol 2014; 25: 1710-1722.
212. Salmon AH, Ferguson JK, Burford JL, et al. Loss of the endothelial glycocalyx links albuminuria and vascular dysfunction. J Am Soc Nephrol 2012; 23: 1339-1350.
213. Williams WW, Taheri D, Tolkoff-Rubin N, Colvin RB,. Clinical role of the renal transplant biopsy. Nat Rev Nephrol 2012; 8: 110-121.
214. Sis B, Jhangri GS, Riopel J, et al. A new diagnostic algorithm for antibody-mediated microcirculation inflammation in kidney transplants. Am J Transplant 2012; 12: 1168-1179.
215. de Kort H, Willicombe M, Brookes P, et al. Microcirculation inflammation associates with outcome in renal transplant patients with de novo donor-specific antibodies. Am J Transplant 2013; 13: 485-492.
216. Qi F, Adair A, Ferenbach D, et al. Depletion of cells of monocyte lineage prevents loss of renal microvasculature in murine kidney transplantation. Transplantation 2008; 86: 1267-1274.
217. Johns EJ, Kopp UC, DiBona GF,. Neural control of renal function. Compr Physiol 2011; 1: 731-767.
218. Bhatt DL, Kandzari DE, O'Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370: 1393-1401.
219. Kim J, Padanilam BJ,. Renal nerves drive interstitial fibrogenesis in obstructive nephropathy. J Am Soc Nephrol 2013; 24: 229-242.
220. Kim J, Padanilam BJ,. Renal denervation prevents long-term sequelae of ischemic renal injury. Kidney Int 2014.
221. Mulder J, Hokfelt T, Knuepfer MM, Kopp UC,. Renal sensory and sympathetic nerves reinnervate the kidney in a similar time-dependent fashion after renal denervation in rats. Am J Physiol Regul Integr Comp Physiol 2013; 304: R675-R682.
222. Shannon JL, Headland R, MacIver AG, Ferryman SR, Barber PC, Howie AJ,. Studies on the innervation of human renal allografts. J Pathol 1998; 186: 109-115.
223. Burnier M, Zanchi A,. Blockade of the renin-angiotensin-aldosterone system: A key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens 2006; 24: 11-25.
224. Del Prete D, Ceol M, Anglani F, et al. Early activation of fibrogenesis in transplanted kidneys: A study on serial renal biopsies. Exp Mol Pathol 2009; 87: 141-145.
225. Amuchastegui SC, Azzollini N, Mister M, Pezzotta A, Perico N, Remuzzi G,. Chronic allograft nephropathy in the rat is improved by angiotensin II receptor blockade but not by calcium channel antagonism. J Am Soc Nephrol 1998; 9: 1948-1955.
226. Zhang JD, Patel MB, Griffiths R, et al. Type 1 angiotensin receptors on macrophages ameliorate IL-1 receptor-mediated kidney fibrosis. J Clin Invest 2014; 124: 2198-2203.
227. Laouari D, Burtin M, Phelep A, et al. TGF-alpha mediates genetic susceptibility to chronic kidney disease. J Am Soc Nephrol 2011; 22: 327-335.
228. Lautrette A, Li S, Alili R, et al. Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: A new therapeutic approach. Nat Med 2005; 11: 867-874.
229. Heinze G, Mitterbauer C, Regele H, et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 2006; 17: 889-899.
230. Opelz G, Zeier M, Laux G, Morath C, Dohler B,. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: A collaborative transplant study report. J Am Soc Nephrol 2006; 17: 3257-3262.
231. Hiremath S, Fergusson D, Doucette S, Mulay AV, Knoll GA,. Renin angiotensin system blockade in kidney transplantation: A systematic review of the evidence. Am J Transplant 2007; 7: 2350-2360.
232. Ibrahim HN, Jackson S, Connaire J, et al. Angiotensin II blockade in kidney transplant recipients. J Am Soc Nephrol 2013; 24: 320-327.
233. Tylicki L, Biedunkiewicz B, Chamienia A, et al. Renal allograft protection with angiotensin II type 1 receptor antagonists. Am J Transplant 2007; 7: 243-248.
234. Siddiqui I, Khan ZA, Lian D, et al. Endothelin-mediated oncofetal fibronectin expression in chronic allograft nephropathy. Transplantation 2006; 82: 406-414.
235. Frank K, Zeier M, Gross ML, Waldherr R, Ritz E, Amann K,. Comprehensive immunohistological analysis of the endothelin system in human kidney grafts. Nephrol Dial Transplant 2006; 21: 1365-1372.
236. Takeda M, Ishida T, Ishimura T, Fujisawa M,. Correlation between endothelin expression in early post-transplant biopsy specimens and long-term allograft function in living-related renal transplantation. Clin Transplant 2006; 20: 26-29.
237. Slowinski T, Subkowski T, Diehr P, et al. Activity of the endothelin system in kidney allograft recipients is not associated with progression of chronic graft dysfunction. Clinical Science 2002; 103: 393S-395S.
238. Gottmann U, van der Woude FJ, Braun C,. Endothelin receptor antagonists: A new therapeutic option for improving the outcome after solid organ transplantation. Curr Vasc Pharmacol 2003; 1: 281-299.
239. Kohan DE, Pollock DM,. Endothelin antagonists for diabetic and non-diabetic chronic kidney disease. Br J Clin Pharmacol 2013; 76: 573-579.
240. Shehata M, Cope GH, Johnson TS, Raftery AT, el Nahas AM,. Cyclosporine enhances the expression of TGF-beta in the juxtaglomerular cells of the rat kidney. Kidney Int 1995; 48: 1487-1496.
241. Hanssen L, Alidousty C, Djudjaj S, et al. YB-1 is an early and central mediator of bacterial and sterile inflammation in vivo. J Immunol 2013; 191: 2604-2613.
242. Oberbauer R,. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: A systematic review of randomized trials. Am J Transplant 2005; 5: 3023.
243. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562-2575.
244. Servais A, Meas-Yedid V, Toupance O, et al. Interstitial fibrosis quantification in renal transplant recipients randomized to continue cyclosporine or convert to sirolimus. Am J Transplant 2009; 9: 2552-2560.
245. Mjornstedt L, Sorensen SS, von Zur Muhlen, et al. Renal function three years after early conversion from a calcineurin inhibitor to everolimus: Results from a randomized trial in kidney transplantation. Transpl Int 2014.
246. Rostaing L, Massari P, Garcia VD, et al. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: A randomized phase II study. Clin J Am Soc Nephrol 2011; 6: 430-439.
247. Rostaing L, Vincenti F, Grinyo J, et al. Long-term belatacept exposure maintains efficacy and safety at 5 years: Results from the long-term extension of the BENEFIT study. Am J Transplant 2013; 13: 2875-2883.
248. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR,. Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation 2004; 78: 242-249.
249. Heilman RL, Devarapalli Y, Chakkera HA, et al. Impact of subclinical inflammation on the development of interstitial fibrosis and tubular atrophy in kidney transplant recipients. Am J Transplant 2010; 10: 563-570.
250. Choi BS, Shin MJ, Shin SJ, et al. Clinical significance of an early protocol biopsy in living-donor renal transplantation: Ten-year experience at a single center. Am J Transplant 2005; 5: 1354-1360.
251. Wynn TA, Ramalingam TR,. Mechanisms of fibrosis: Therapeutic translation for fibrotic disease. Nat Med 2012; 18: 1028-1040.
252. Meng XM, Chung AC, Lan HY,. Role of the TGF-beta/BMP-7/Smad pathways in renal diseases. Clin Sci 2013; 124: 243-254.
253. Yanagita M,. Inhibitors/antagonists of TGF-beta system in kidney fibrosis. Nephrol Dial Transplant 2012; 27: 3686-3691.
254. Tossidou I, Schiffer M,. TGF-beta/BMP pathways and the podocyte. Semin Nephrol 2012; 32: 368-376.
255. Djamali A, Samaniego M,. Fibrogenesis in kidney transplantation: Potential targets for prevention and therapy. Transplantation 2009; 88: 1149-1156.
256. Liu Y,. Renal fibrosis: New insights into the pathogenesis and therapeutics. Kidney Int 2006; 69: 213-217.
257. Yin Z, Xia Y, Luo C, Zhang J, He Y, Wu X,. Effects of silencing transforming growth factor-beta1 by RNA interference plasmid on rat renal allograft fibrosis using Smads pathway. Urology 2011; 77: e761-e767.
258. Guan Q, Li S, Gao S, Chen H, Nguan CY, Du C,. Reduction of chronic rejection of renal allografts by anti-transforming growth factor-beta antibody therapy in a rat model. Am J Physiol Renal Physiol 2013; 305: F199-F207.
259. Chen X, Wang H, Liao HJ, et al. Integrin-mediated type II TGF-beta receptor tyrosine dephosphorylation controls SMAD-dependent profibrotic signaling. J Clin Invest 2014; 124: 3295-3310.
260. Kato M,. TGF-beta-induced signaling circuit loops mediated by microRNAs as new therapeutic targets for renal fibrosis. Kidney Int 2013; 84: 1067-1069.
261. Zeisberg M, Bottiglio C, Kumar N, et al. Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models. Am J Physiol Renal Physiol 2003; 285: F1060-F1067.
262. Tanaka M, Asada M, Higashi AY, et al. Loss of the BMP antagonist USAG-1 ameliorates disease in a mouse model of the progressive hereditary kidney disease Alport syndrome. J Clin Invest 2010; 120: 768-777.
263. Sugimoto H, LeBleu VS, Bosukonda D, et al. Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis. Nat Med 2012; 18: 396-404.
264. Gai Z, Zhou G, Gui T, et al. Trps1 haploinsufficiency promotes renal fibrosis by increasing Arkadia expression. J Am Soc Nephrol 2010; 21: 1468-1476.
265. Dendooven A, van Oostrom O, van der Giezen DM, et al. Loss of endogenous bone morphogenetic protein-6 aggravates renal fibrosis. Am J Pathol 2011; 178: 1069-1079.
266. Grgurevic L, Macek B, Healy DR, et al. Isoform increases renal fibrosis. Circulating Bone Morphogenetic Protein 2011; 22: 1-3.
267. Wei X, Xia Y, Li F, et al. Kindlin-2 mediates activation of TGF-beta/Smad signaling and renal fibrosis. J Am Soc Nephrol 2013; 24: 1387-1398.
268. Soofi A, Zhang P, Dressler GR,. Kielin/chordin-like protein attenuates both acute and chronic renal injury. J Am Soc Nephrol 2013; 24: 897-905.
269. Tyler JR, Robertson H, Booth TA, Burt AD, Kirby JA,. Chronic allograft nephropathy: Intraepithelial signals generated by transforming growth factor-beta and bone morphogenetic protein-7. Am J Transplant 2006; 6: 1367-1376.
270. Djamali A, Vidyasagar A, Yagci G, Huang LJ, Reese S,. Mycophenolic acid may delay allograft fibrosis by inhibiting transforming growth factor-beta1-induced activation of Nox-2 through the nuclear factor-kappaB pathway. Transplantation 2010; 90: 387-393.
271. Wu MJ, Wen MC, Chiu YT, Chiou YY, Shu KH, Tang MJ,. Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis. Kidney Int 2006; 69: 2029-2036.
272. Liu M, Gu M, Wu Y, et al. Therapeutic effect of Y-27632 on chronic allograft nephropathy in rats. J Surg Res 2009; 157: e-127.
273. Wolf G,. Novel aspects of the renin-angiotensin-aldosterone-system. Front Biosci 2008; 13: 4993-5005.
274. Ito I, Waku T, Aoki M, et al. A nonclassical vitamin D receptor pathway suppresses renal fibrosis. J Clin Invest 2013; 123: 4579-4594.
275. Zhang Y, Kong J, Deb DK, Chang A, Li YC,. Vitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin system. J Am Soc Nephrol 2010; 21: 966-973.
276. Garber K,. Companies waver in efforts to target transforming growth factor beta in cancer. J Natl Cancer Inst 2009; 101: 1664-1667.
277. Shull MM, Ormsby I, Kier AB, et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992; 359: 693-699.
278. Eikmans M, Sijpkens YW, Baelde HJ, de Heer E, Paul LC, Bruijn JA,. High transforming growth factor-beta and extracellular matrix mRNA response in renal allografts during early acute rejection is associated with absence of chronic rejection. Transplantation 2002; 73: 573-579.
279. Khanna AK, Cairns VR, Becker CG, Hosenpud JD,. Transforming growth factor (TGF)-beta mimics and anti-TGF-beta antibody abrogates the in vivo effects of cyclosporine: Demonstration of a direct role of TGF-beta in immunosuppression and nephrotoxicity of cyclosporine. Transplantation 1999; 67: 882-889.
280. Khanna AK, Plummer MS, Hilton G, Pieper GM, Ledbetter S,. Anti-transforming growth factor antibody at low but not high doses limits cyclosporine-mediated nephrotoxicity without altering rat cardiac allograft survival: Potential of therapeutic applications. Circulation 2004; 110: 3822-3829.
281. Booth AJ, Csencsits-Smith K, Wood SC, Lu G, Lipson KE, Bishop DK,. Connective tissue growth factor promotes fibrosis downstream of TGFbeta and IL-6 in chronic cardiac allograft rejection. Am J Transplant 2010; 10: 220-230.
282. Nguyen TQ, Roestenberg P, van Nieuwenhoven FA, et al. CTGF inhibits BMP-7 signaling in diabetic nephropathy. J Am Soc Nephrol 2008; 19: 2098-2107.
283. Kok HM, Falke LL, Goldschmeding R, Nguyen TQ, Targeting CTGF,. EGF and PDGF pathways to prevent progression of kidney disease. Nat Rev Nephrol 2014; 10: 700-711.
284. Cheng O, Thuillier R, Sampson E, et al. Connective tissue growth factor is a biomarker and mediator of kidney allograft fibrosis. Am J Transplant 2006; 6: 2292-2306.
285. Luo GH, Lu YP, Song J, Yang L, Shi YJ, Li YP,. Inhibition of connective tissue growth factor by small interfering RNA prevents renal fibrosis in rats undergoing chronic allograft nephropathy. Transplant Proc 2008; 40: 2365-2369.
286. Liu Y, Yang J,. Hepatocyte growth factor: New arsenal in the fights against renal fibrosis. Kidney Int 2006; 70: 238-240.
287. Mizuno S, Matsumoto K, Kurosawa T, Mizuno-Horikawa Y, Nakamura T,. Reciprocal balance of hepatocyte growth factor and transforming growth factor-beta 1 in renal fibrosis in mice. Kidney Int 2000; 57: 937-948.
288. Gong R, Rifai A, Tolbert EM, Centracchio JN, Dworkin LD,. Hepatocyte growth factor modulates matrix metalloproteinases and plasminogen activator/plasmin proteolytic pathways in progressive renal interstitial fibrosis. J Am Soc Nephrol 2003; 14: 3047-3060.
289. Dworkin LD, Gong R, Tolbert E, et al. Hepatocyte growth factor ameliorates progression of interstitial fibrosis in rats with established renal injury. Kidney Int 2004; 65: 409-419.
290. Yang J, Dai C, Liu Y,. Hepatocyte growth factor gene therapy and angiotensin II blockade synergistically attenuate renal interstitial fibrosis in mice. J Am Soc Nephrol 2002; 13: 2464-2477.
291. Azuma H, Takahara S, Matsumoto K, et al. Hepatocyte growth factor prevents the development of chronic allograft nephropathy in rats. J Am Soc Nephrol 2001; 12: 1280-1292.
292. Herrero-Fresneda I, Torras J, Franquesa M, et al. HGF gene therapy attenuates renal allograft scarring by preventing the profibrotic inflammatory-induced mechanisms. Kidney Int 2006; 70: 265-274.
293. Benvenuti S, Comoglio PM,. The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol 2007; 213: 316-325.
294. Ostendorf T, Eitner F, Floege J,. The PDGF family in renal fibrosis. Pediatr Nephrol 2012; 27: 1041-1050.
295. Boor P, Ostendorf T, Floege J,. PDGF and the progression of renal disease. Nephrol Dial Transpl 2014; 29: I45-I54.
296. Chen YT, Chang FC, Wu CF, et al. Platelet-derived growth factor receptor signaling activates pericyte-myofibroblast transition in obstructive and post-ischemic kidney fibrosis. Kidney Int 2011; 80: 1170-1181.
297. Kliem V, Johnson RJ, Alpers CE, et al. Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6-nephrectomized rats. Kidney Int 1996; 49: 666-678.
298. Eitner F, Bucher E, van Roeyen C, et al. PDGF-C is a proinflammatory cytokine that mediates renal interstitial fibrosis. J Am Soc Nephrol 2008; 19: 281-289.
299. Taneda S, Hudkins KL, Topouzis S, et al. Obstructive uropathy in mice and humans: Potential role for PDGF-D in the progression of tubulointerstitial injury. J Am Soc Nephrol 2003; 14: 2544-2555.
300. Ding H, Wu X, Bostrom H, et al. A specific requirement for PDGF-C in palate formation and PDGFR-alpha signaling. Nat Genet 2004; 36: 1111-1116.
301. Ostendorf T, Kunter U, van Roeyen C, et al. The effects of platelet-derived growth factor antagonism in experimental glomerulonephritis are independent of the transforming growth factor-beta system. J Am Soc Nephrol 2002; 13: 658-667.
302. Jechlinger M, Podsypanina K, Varmus H,. Regulation of transgenes in three-dimensional cultures of primary mouse mammary cells demonstrates oncogene dependence and identifies cells that survive deinduction. Genes Dev 2009; 23: 1677-1688.
303. Alpers CE, Davis CL, Barr D, Marsh CL, Hudkins KL,. Identification of platelet-derived growth factor A and B chains in human renal vascular rejection. Am J Pathol 1996; 148: 439-451.
304. Szabo A, Lutz J, Schleimer K, et al. Effect of angiotensin-converting enzyme inhibition on growth factor mRNA in chronic renal allograft rejection in the rat. Kidney Int 2000; 57: 982-991.
305. Savikko J, Teppo AM, Taskinen E, von Willebrand E,. Different effects of tacrolimus and cyclosporine on PDGF induction and chronic allograft injury: Evidence for improved kidney graft outcome. Transplant immunology 2014.
306. Boersema M, Katta K, Rienstra H, et al. Local medial microenvironment directs phenotypic modulation of smooth muscle cells after experimental renal transplantation. Am J Transplant 2012; 12: 1429-1440.
307. Yamada K, Hatakeyama E, Sakamaki T, et al. Involvement of platelet-derived growth factor and histocompatibility of DRB 1 in chronic renal allograft nephropathy. Transplantation 2001; 71: 936-941.
308. Liu G, Changsirikulchai S, Hudkins KL, et al. Identification of platelet-derived growth factor D in human chronic allograft nephropathy. Hum Pathol 2008; 39: 393-402.
309. Savikko J, Rintala J, von Willebrand E,. Early short-term platelet-derived growth factor inhibition prevents the development of chronic allograft nephropathy in experimental rat kidney transplantation. Transplant Proc 2006; 38: 3231-3232.
310. Charo IF, Ransohoff RM,. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006; 354: 610-621.
311. Sarvaiya PJ, Guo D, Ulasov I, Gabikian P, Lesniak MS,. Chemokines in tumor progression and metastasis. Oncotarget 2013; 4: 2171-2185.
312. Vielhauer V, Anders HJ,. Chemokines and chemokine receptors as therapeutic targets in chronic kidney disease. Front Biosci 2009; 1: 1-12.
313. Neusser MA, Kraus AK, Regele H, et al. The chemokine receptor CXCR7 is expressed on lymphatic endothelial cells during renal allograft rejection. Kidney Int 2010; 77: 801-808.
314. Zhou HL, Wang YT, Gao T, Wang WG, Wang YS,. Distribution and expression of fibroblast-specific protein chemokine CCL21 and chemokine receptor CCR7 in renal allografts. Transplant Proc 2013; 45: 538-545.
315. Lazzeri E, Rotondi M, Mazzinghi B, et al. High CXCL10 expression in rejected kidneys and predictive role of pretransplant serum CXCL10 for acute rejection and chronic allograft nephropathy. Transplantation 2005; 79: 1215-1220.
316. Hoffmann U, Segerer S, Rummele P, et al. Expression of the chemokine receptor CXCR3 in human renal allografts-A prospective study. Nephrol Dial Transplant 2006; 21: 1373-1381.
317. Ho J, Rush DN, Gibson IW, et al. Early urinary CCL2 is associated with the later development of interstitial fibrosis and tubular atrophy in renal allografts. Transplantation 2010; 90: 394-400.
318. Ho J, Wiebe C, Gibson IW, et al. Elevated urinary CCL2: Cr at 6 months is associated with renal allograft interstitial fibrosis and inflammation at 24 months. Transplantation 2014; 98: 39-46.
319. Hricik DE, Nickerson P, Formica RN, et al. Multicenter validation of urinary CXCL9 as a risk-stratifying biomarker for kidney transplant injury. Am J Transplant 2013; 13: 2634-2644.
320. Dikow R, Becker LE, Schaier M, Waldherr R, Gross ML, Zeier M,. In renal transplants with delayed graft function chemokines and chemokine receptor expression predict long-term allograft function. Transplantation 2010; 90: 771-776.
321. Bedke J, Kiss E, Schaefer L, et al. Beneficial effects of CCR1 blockade on the progression of chronic renal allograft damage. Am J Transplant 2007; 7: 527-537.
322. Song E, Zou H, Yao Y, et al. Early application of Met-RANTES ameliorates chronic allograft nephropathy. Kidney Int 2002; 61: 676-685.
323. Djamali A,. Oxidative stress as a common pathway to chronic tubulointerstitial injury in kidney allografts. Am J Physiol Renal Physiol 2007; 293: F445-F455.
324. Djamali A, Vidyasagar A, Adulla M, Hullett D, Reese S,. Nox-2 is a modulator of fibrogenesis in kidney allografts. Am J Transplant 2009; 9: 74-82.
325. Djamali A, Reese S, Hafez O, et al. Nox2 is a mediator of chronic CsA nephrotoxicity. Am J Transplant 2012; 12: 1997-2007.
326. Albrecht EW, van Goor H, Smit-van Oosten, Stegeman A,. Long-term dietary l -arginine supplementation attenuates proteinuria and focal glomerulosclerosis in experimental chronic renal transplant failure. Nitric Oxide 2003; 8: 53-58.
327. Gottmann U, Oltersdorf J, Schaub M, et al. Oxidative stress in chronic renal allograft nephropathy in rats: Effects of long-term treatment with carvedilol, BM 91. 0228, or alpha-tocopherol. J Cardiovasc Pharmacol 2003; 42: 442-450.
328. Gill PS, Wilcox CS,. NADPH oxidases in the kidney. Antioxid Redox Signal 2006; 8: 1597-1607.
329. Hinz B, Phan SH, Thannickal VJ, et al. Recent developments in myofibroblast biology: Paradigms for connective tissue remodeling. Am J Pathol 2012; 180: 1340-1355.
330. Bechtel W, McGoohan S, Zeisberg EM, et al. Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med 2010; 16: 544-550.
331. Tampe B, Tampe D, Muller CA, et al. Tet3-mediated hydroxymethylation of epigenetically silenced genes contributes to bone morphogenic protein 7-induced reversal of kidney fibrosis. J Am Soc Nephrol 2014; 25: 905-912.
332. Reddy MA, Sumanth P, Lanting L, et al. Losartan reverses permissive epigenetic changes in renal glomeruli of diabetic db/db mice. Kidney Int 2014; 85: 362-373.
333. Ko YA, Mohtat D, Suzuki M, et al. Cytosine methylation changes in enhancer regions of core pro-fibrotic genes characterize kidney fibrosis development. Genome Biol 2013; 14: R108.
334. Chen J, Zmijewska A, Zhi D, Mannon RB,. Cyclosporine-mediated allograft fibrosis is associated with micro-rna 21 through akt signaling. Transplant Int 2014.
335. Gomez IG, Grafals M, Portilla D, Duffield JS,. MicroRNAs as potential therapeutic targets in kidney disease. J Formos Med Assoc 2013; 112: 237-243.
336. Wilflingseder J, Regele H, Perco P, et al. MiRNA profiling discriminates types of rejection and injury in human renal allografts. Transplantation 2013; 95: 835-841.
337. Chau BN, Xin C, Hartner J, et al. MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways. Sci Transl Med 2012; 4: 121ra118.
338. Denby L, Ramdas V, Lu R, et al. MicroRNA-214 antagonism protects against renal fibrosis. J Am Soc Nephrol 2014; 25: 65-80.
339. Chung AC, Huang XR, Meng X, Lan HY,. MiR-192 mediates TGF-beta/Smad3-driven renal fibrosis. J Am Soc Nephrol 2010; 21: 1317-1325.
340. Wang B, Komers R, Carew R, et al. Suppression of microRNA-29 expression by TGF-beta1 promotes collagen expression and renal fibrosis. J Am Soc Nephrol 2012; 23: 252-265.
341. Oba S, Kumano S, Suzuki E, et al. MiR-200b precursor can ameliorate renal tubulointerstitial fibrosis. PLoS ONE 2010; 5: e13614.
342. Jiang L, Qiu W, Zhou Y, et al. A microRNA-30e/mitochondrial uncoupling protein 2 axis mediates TGF-beta1-induced tubular epithelial cell extracellular matrix production and kidney fibrosis. Kidney Int 2013; 84: 285-296.
343. Eddy AA,. Can renal fibrosis be reversed. Pediatr Nephrol 2005; 20: 1369-1375.
344. Lopez-Guisa JM, Cai X, Collins SJ, et al. Mannose receptor 2 attenuates renal fibrosis. J Am Soc Nephrol 2012; 23: 236-251.
345. Guerrot D, Kerroch M, Placier S, et al. Discoidin domain receptor 1 is a major mediator of inflammation and fibrosis in obstructive nephropathy. Am J Pathol 2011; 179: 83-91.
346. Gross O, Girgert R, Beirowski B, et al. Loss of collagen-receptor DDR1 delays renal fibrosis in hereditary type IV collagen disease. Matrix Biol 2010; 29: 346-356.
347. Kato N, Kosugi T, Sato W, et al. Basigin/CD147 promotes renal fibrosis after unilateral ureteral obstruction. Am J Pathol 2011; 178: 572-579.
348. He C, Zhao C, Kumar A, et al. Vasoprotective effect of PDGF-CC mediated by HMOX1 rescues retinal degeneration. Proc Natl Acad Sci USA 2014; 111: 14806-14811.
349. Shweke N, Boulos N, Jouanneau C, et al. Tissue transglutaminase contributes to interstitial renal fibrosis by favoring accumulation of fibrillar collagen through TGF-beta activation and cell infiltration. Am J Pathol 2008; 173: 631-642.
350. Huang L, Haylor JL, Hau Z, et al. Transglutaminase inhibition ameliorates experimental diabetic nephropathy. Kidney Int 2009; 76: 383-394.
351. Lennon R, Byron A, Humphries JD, et al. Global analysis reveals the complexity of the human glomerular extracellular matrix. J Am Soc Nephrol 2014; 25: 939-951.
352. van Roeyen CR, Boor P, Borkham-Kamphorst E, et al. A novel, dual role of CCN3 in experimental glomerulonephritis: Pro-Angiogenic and antimesangioproliferative effects. Am J Pathol 2012; 180: (5):.
353. van Roeyen CR, Eitner F, Scholl T, et al. CCN3 is a novel endogenous PDGF-regulated inhibitor of glomerular cell proliferation. Kidney Int 2008; 73: 86-94.
354. Scruggs BS, Zuo Y, Donnert E, Ma L, Bertram JF, Fogo AB,. Increased capillary branching contributes to angiotensin type 1 receptor blocker (ARB)-induced regression of sclerosis. Am J Pathol 2011; 178: 1891-1898.
355. Gagliardini E, Corna D, Zoja C, et al. Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes. Am J Physiol Renal Physiol 2009; 297: F1448-F1456.
356. Chatziantoniou C, Dussaule JC,. Insights into the mechanisms of renal fibrosis: Is it possible to achieve regression. Am J Physiol Renal Physiol 2005; 289: F227-F234.
357. Sugimoto H, Grahovac G, Zeisberg M, Kalluri R,. Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors. Diabetes 2007; 56: 1825-1833.
358. Zeisberg M, Hanai J, Sugimoto H, et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 2003; 9: 964-968.
359. Duffield JS, Lupher M, Thannickal VJ, Wynn TA,. Host responses in tissue repair and fibrosis. Annual Review of Pathology 2013; 8: 241-276.
360. Johnson TS, Abo-Zenah H, Skill JN, et al. Tissue transglutaminase: A mediator and predictor of chronic allograft nephropathy. Transplantation 2004; 77: 1667-1675.
361. Gerth J, Busch M, Illner N, Traut M, Grone HJ, Wolf G,. Are tissue samples from two different anatomical areas of the kidney necessary for adequate diagnosis. Clin Nephrol 2010; 74: 258-265.
362. Meas-Yedid V, Servais A, Noel LH, et al. New computerized color image analysis for the quantification of interstitial fibrosis in renal transplantation. Transplantation 2011; 92: 890-899.
363. Servais A, Meas-Yedid V, Noel LH, et al. Interstitial fibrosis evolution on early sequential screening renal allograft biopsies using quantitative image analysis. Am J Transplant 2011; 11: 1456-1463.
364. Farris AB, Adams CD, Brousaides N, et al. Morphometric and visual evaluation of fibrosis in renal biopsies. J Am Soc Nephrol 2011; 22: 176-186.
365. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD,. Delta analysis of posttransplantation tubulointerstitial damage. Transplantation 2004; 78: 434-441.
366. Kers J, Xu-Dubois YC, Rondeau E, et al. Intragraft tubular vimentin and CD44 expression correlate with long-term renal allograft function and interstitial fibrosis and tubular atrophy. Transplantation 2010; 90: 502-509.
367. Fatima H, Moeller MJ, Smeets B, et al. Parietal epithelial cell activation marker in early recurrence of FSGS in the transplant. Clin J Am Soc Nephrol 2012; 7: 1852-1858.
368. Steegh FM, Gelens MA, Nieman FH, et al. Early loss of peritubular capillaries after kidney transplantation. J Am Soc Nephrol 2011; 22: 1024-1029.
369. Akalin E, O'Connell PJ,. Genomics of chronic allograft injury. Kidney Int Suppl 2010; 119: S33-S37.
370. Sagoo P, Perucha E, Sawitzki B, et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest 2010; 120: 1848-1861.
371. Halloran PF, de Freitas DG, Einecke G, et al. An integrated view of molecular changes, histopathology and outcomes in kidney transplants. Am J Transplant 2010; 10: 2223-2230.
372. Halloran PF, de Freitas DG, Einecke G, et al. The molecular phenotype of kidney transplants. Am J Transplant 2010; 10: 2215-2222.
373. Mengel M, Chang J, Kayser D, et al. The molecular phenotype of 6-week protocol biopsies from human renal allografts: Reflections of prior injury but not future course. Am J Transplant 2011; 11: 708-718.
374. Einecke G, Reeve J, Sis B, et al. A molecular classifier for predicting future graft loss in late kidney transplant biopsies. J Clin Invest 2010; 120: 1862-1872.
375. Mueller TF, Einecke G, Reeve J, et al. Microarray analysis of rejection in human kidney transplants using pathogenesis-based transcript sets. Am J Transplant 2007; 7: 2712-2722.
376. Loupy A, Lefaucheur C, Vernerey D, et al. Molecular microscope strategy to improve risk stratification in early antibody-mediated kidney allograft rejection. J Am Soc Nephrol 2014; 25: 2267-2277.
377. Scian MJ, Maluf DG, Archer KJ, et al. Gene expression changes are associated with loss of kidney graft function and interstitial fibrosis and tubular atrophy: Diagnosis versus prediction. Transplantation 2011; 91: 657-665.
378. Dean PG, Park WD, Cornell LD, Gloor JM, Stegall MD,. Intragraft gene expression in positive crossmatch kidney allografts: Ongoing inflammation mediates chronic antibody-mediated injury. Am J Transplant 2012; 12: 1551-1563.
379. Genovese F, Manresa AA, Leeming DJ, Karsdal MA, Boor P,. The extracellular matrix in the kidney: A source of novel non-invasive biomarkers of kidney fibrosis. Fibrogenesis Tissue Repair 2014; 7: 4.
380. Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592.
381. Kendrick J, Cheung AK, Kaufman JS, et al. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 2011; 22: 1913-1922.
382. Isakova T, Xie H, Yang W, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305: 2432-2439.
383. Bolignano D, Lacquaniti A, Coppolino G, et al. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 337-344.
384. Malyszko J, Malyszko JS, Bachorzewska-Gajewska H, Poniatowski B, Dobrzycki S, Mysliwiec M,. Neutrophil gelatinase-associated lipocalin is a new and sensitive marker of kidney function in chronic kidney disease patients and renal allograft recipients. TransplantProc 2009; 41: 158-161.
385. Peralta CA, Katz R, Bonventre JV, et al. Associations of urinary levels of kidney injury molecule 1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) with kidney function decline in the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis 2012; 60: 904-911.
386. Lim AI, Tang SC, Lai KN, Leung JC,. Kidney injury molecule-1: More than just an injury marker of tubular epithelial cells. J Cell Physiol 2013; 228: 917-924.
387. van Timmeren MM, van den Heuvel MC, Bailly V, Bakker SJ, van GH, Stegeman CA,. Tubular kidney injury molecule-1 (KIM-1) in human renal disease. J Pathol 2007; 212: 209-217.
388. Sabbisetti VS, Waikar SS, Antoine DJ, et al. Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes. J Am Soc Nephrol 2014; 25: 2177-2186.
389. Meersch M, Schmidt C, Van Aken H, et al. Urinary TIMP-2 and IGFBP7 as early biomarkers of acute kidney injury and renal recovery following cardiac surgery. PLoS ONE 2014; 9: e.
390. Kamijo A, Kimura K, Sugaya T, et al. Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease. J Lab Clin Med 2004; 143: 23-30.
391. Tanaka T, Doi K, Maeda-Mamiya R, et al. Urinary L-type fatty acid-binding protein can reflect renal tubulointerstitial injury. Am J Pathol 2009; 174: 1203-1211.
392. Fassett RG, Venuthurupalli SK, Gobe GC, Coombes JS, Cooper MA, Hoy WE,. Biomarkers in chronic kidney disease: A review. Kidney Int 2011; 80: 806-821.
393. Malyszko J,. Biomarkers of acute kidney injury in different clinical settings: A time to change the paradigm. Kidney Blood Press Res 2010; 33: 368-382.
394. Heyne N, Kemmner S, Schneider C, Nadalin S, Konigsrainer A, Haring HU,. Urinary neutrophil gelatinase-associated lipocalin accurately detects acute allograft rejection among other causes of acute kidney injury in renal allograft recipients. Transplantation 2012; 93: 1252-1257.
395. Roth GA, Lebherz-Eichinger D, Ankersmit HJ, et al. Increased total cytokeratin-18 serum and urine levels in chronic kidney disease. Clin Chim Acta 2011; 412: 713-717.
396. Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C,. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: A competing risks modeling approach. J Am Soc Nephrol 2005; 16: 2449-2455.
397. Chen J, Hamm LL, Kleinpeter MA, et al. Elevated plasma levels of endostatin are associated with chronic kidney disease. Am J Nephrol 2012; 35: 335-340.
398. Metalidis C, van Vuuren SH, Broekhuizen R, et al. Urinary connective tissue growth factor is associated with human renal allograft fibrogenesis. Transplantation 2013; 96: 494-500.
399. Rogier E, Durrbach A, Abecassis L, et al. A novel biological assay to detect the active form of TGF-beta in urine to monitor renal allograft rejection. Kidney Int 2005; 68: 1875-1883.
400. Ghoul BE, Squalli T, Servais A, et al. Urinary procollagen III aminoterminal propeptide (PIIINP): A fibrotest for the nephrologist. Clin J Am Soc Nephrol 2010; 5: 205-210.
401. Teppo AM, Tornroth T, Honkanen E, Gronhagen-Riska C,. Urinary amino-terminal propeptide of type III procollagen (PIIINP) as a marker of interstitial fibrosis in renal transplant recipients. Transplantation 2003; 75: 2113-2119.
402. Soylemezoglu O, Wild G, Dalley AJ, et al. Urinary and serum type III collagen: Markers of renal fibrosis. Nephrol Dial Transplant 1997; 12: 1883-1889.
403. Morita M, Uchigata Y, Hanai K, Ogawa Y, Iwamoto Y,. Association of urinary type IV collagen with GFR decline in young patients with type 1 diabetes. Am J Kidney Dis 2011; 58: 915-920.
404. Okonogi H, Nishimura M, Utsunomiya Y, et al. Urinary type IV collagen excretion reflects renal morphological alterations and type IV collagen expression in patients with type 2 diabetes mellitus. ClinNephrol 2001; 55: 357-364.
405. Araki S, Haneda M, Koya D, et al. Association between urinary type IV collagen level and deterioration of renal function in type 2 diabetic patients without overt proteinuria. Diabetes Care 2010; 33: 1805-1810.
406. Furumatsu Y, Nagasawa Y, Shoji T, et al. Urinary type IV collagen in nondiabetic kidney disease. Nephron Clin Pract 2011; 117: c160-c16c.
407. Merchant ML, Perkins BA, Boratyn GM, et al. Urinary peptidome may predict renal function decline in type 1 diabetes and microalbuminuria. J Am Soc Nephrol 2009; 20: 2065-2074.
408. Maahs DM, Siwy J, Argiles A, et al. Urinary collagen fragments are significantly altered in diabetes: a link to pathophysiology. PLoS ONE 2010; 5: e13051.
409. Mullen W, Delles C, Mischak H,. Urinary proteomics in the assessment of chronic kidney disease. Curr Opin Nephrol Hypertens 2011; 20: 654-661.
410. Klein J, Kavvadas P, Prakoura N, et al. Renal fibrosis: Insight from proteomics in animal models and human disease. Proteomics 2011; 11: 805-815.
411. Rossing K, Mischak H, Dakna M, et al. Urinary proteomics in diabetes and CKD. J Am Soc Nephrol 2008; 19: 1283-1290.
412. Quintana LF, Banon-Maneus E, Sole-Gonzalez A, Campistol JM,. Urine proteomics biomarkers in renal transplantation: An overview. Transplantation 2009; 88: S45-S49.
413. Quintana LF, Sole-Gonzalez A, Kalko SG, et al. Urine proteomics to detect biomarkers for chronic allograft dysfunction. J Am Soc Nephrol 2009; 20: 428-435.
414. Sigdel TK, Lee S, Sarwal MM,. Profiling the proteome in renal transplantation. Proteomics Clin Appl 2011; 5: 269-280.
415. Miranda KC, Bond DT, McKee M, et al. Nucleic acids within urinary exosomes/microvesicles are potential biomarkers for renal disease. Kidney Int 2010; 78: 191-199.
416. Hartono C, Muthukumar T, Suthanthiran M,. Noninvasive diagnosis of acute rejection of renal allografts. Curr Opin Organ Transplant 2010; 15: 35-41.
417. Anglicheau D, Muthukumar T, Hummel A, et al. Discovery and validation of a molecular signature for the noninvasive diagnosis of human renal allograft fibrosis. Transplantation 2012; 93: 1136-1146.
418. Lee JR, Muthukumar T, Dadhania D, et al. Urinary cell mRNA profiles predictive of human kidney allograft status. Immunol Rev 2014; 258: 218-240.
419. Muthukumar T, Lee JR, Dadhania DM, et al. Allograft rejection and tubulointerstitial fibrosis in human kidney allografts: Interrogation by urinary cell mRNA profiling. Transplant Rev (Orlando) 2014; 28: 145-154.
420. Grenier N, Poulain S, Lepreux S, et al. Quantitative elastography of renal transplants using supersonic shear imaging: A pilot study. Eur Radiol 2012; 22: 2138-2146.
421. Orlacchio A, Chegai F, Del Giudice C, et al. Kidney transplant: Usefulness of real-time elastography (RTE) in the diagnosis of graft interstitial fibrosis. Ultrasound Med Biol 2014; 40: 2564-2572.
422. Gao J, Min R, Hamilton J, et al. Corticomedullary strain ratio: A quantitative marker for assessment of renal allograft cortical fibrosis. J Ultrasound Med 2013; 32: 1769-1775.
423. Gao J, Weitzel W, Rubin JM, et al. Renal transplant elasticity ultrasound imaging: Correlation between normalized strain and renal cortical fibrosis. Ultrasound Med Biol 2013; 39: 1536-1542.
424. Sommerer C, Scharf M, Seitz C, et al. Assessment of renal allograft fibrosis by transient elastography. Transpl Int 2013; 26: 545-551.
425. Syversveen T, Brabrand K, Midtvedt K, et al. Assessment of renal allograft fibrosis by acoustic radiation force impulse quantification-A pilot study. Transpl Int 2011; 24: 100-105.
426. Lee CU, Glockner JF, Glaser KJ, et al. MR elastography in renal transplant patients and correlation with renal allograft biopsy: A feasibility study. Acad Radiol 2012; 19: 834-841.
427. Eisenberger U, Thoeny HC, Binser T, et al. Evaluation of renal allograft function early after transplantation with diffusion-weighted MR imaging. Eur Radiol 2010; 20: 1374-1383.
428. Thoeny HC, Binser T, Roth B, Kessler TM, Vermathen P,. Noninvasive assessment of acute ureteral obstruction with diffusion-weighted MR imaging: A prospective study. Radiology 2009; 252: 721-728.
429. Thoeny HC, De Keyzer F,. Diffusion-weighted MR imaging of native and transplanted kidneys. Radiology 2011; 259: 25-38.
430. Thoeny HC, De Keyzer F, Oyen RH, Peeters RR,. Diffusion-weighted MR imaging of kidneys in healthy volunteers and patients with parenchymal diseases: Initial experience. Radiology 2005; 235: 911-917.
431. Thoeny HC, Zumstein D, Simon-Zoula S, et al. Functional evaluation of transplanted kidneys with diffusion-weighted and BOLD MR imaging: Initial experience. Radiology 2006; 241: 812-821.
432. Vermathen P, Binser T, Boesch C, Eisenberger U, Thoeny HC,. Three-year follow-up of human transplanted kidneys by diffusion-weighted MRI and blood oxygenation level-dependent imaging. J Magn Reson Imaging 2012; 35: 1133-1138.
433. Togao O, Doi S, Kuro-o M, Masaki T, Yorioka N, Takahashi M,. Assessment of renal fibrosis with diffusion-weighted MR imaging: Study with murine model of unilateral ureteral obstruction. Radiology 2010; 255: 772-780.
434. Yang D, Ye Q, Williams DS, Hitchens TK, Ho C,. Normal and transplanted rat kidneys: Diffusion MR imaging at 7 T. Radiology 2004; 231: 702-709.
435. Carbone SF, Gaggioli E, Ricci V, Mazzei F, Mazzei MA, Volterrani L,. Diffusion-weighted magnetic resonance imaging in the evaluation of renal function: A preliminary study. Radiol Med 2007; 112: 1201-1210.
436. Namimoto T, Yamashita Y, Mitsuzaki K, Nakayama Y, Tang Y, Takahashi M,. Measurement of the apparent diffusion coefficient in diffuse renal disease by diffusion-weighted echo-planar MR imaging. J Magn Reson Imaging 1999; 9: 832-837.
437. Inoue T, Kozawa E, Okada H, et al. Noninvasive evaluation of kidney hypoxia and fibrosis using magnetic resonance imaging. J Am Soc Nephrol 2011; 22: 1429-1434.
438. Boor P, Perkuhn M, Weibrecht M, et al. Diffusion-weighted MR imaging does not reflect kidney fibrosis in rat model of fibrosis. J Magn Reson Imaging 2015; DOI: 10.1002/jmri.24853
439. Tampe B, Zeisberg M,. Contribution of genetics and epigenetics to progression of kidney fibrosis. Nephrol Dial Transplant 2014; 29: iv72-iv79.
440. Samuels JA, Molony DA,. Randomized controlled trials in nephrology: State of the evidence and critiquing the evidence. Adv Chronic Kidney Dis 2012; 19: 40-46.
441. Miyata T, Ando T, Hiragi H, et al. Drug discovery in renal disease-Towards a more efficient framework. Nat Rev Nephrol 2014; 10: 290-296.
442. Prakash J, de Borst MH, van Loenen-Weemaes AM, et al. Cell-specific delivery of a transforming growth factor-beta type I receptor kinase inhibitor to proximal tubular cells for the treatment of renal fibrosis. Pharm Res 2008; 25: 2427-2439.
443. Kamada H, Tsutsumi Y, Sato-Kamada K, et al. Synthesis of a poly(vinylpyrrolidone-co-dimethyl maleic anhydride) co-polymer and its application for renal drug targeting. Nat Biotechnol 2003; 21: 399-404.
444. Asgeirsdottir SA, Kamps JA, Bakker HI, et al. Site-specific inhibition of glomerulonephritis progression by targeted delivery of dexamethasone to glomerular endothelium. Mol Pharmacol 2007; 72: 121-131.
445. Asgeirsdottir SA, Zwiers PJ, Morselt HW, et al. Inhibition of proinflammatory genes in anti-GBM glomerulonephritis by targeted dexamethasone-loaded AbEsel liposomes. Am J Physiol Renal Physiol 2008; 294: F554-F561.
446. Choi CH, Zuckerman JE, Webster P, Davis ME,. Targeting kidney mesangium by nanoparticles of defined size. Proc Natl Acad Sci USA 2011; 108: 6656-6661.
447. Dolman ME, Harmsen S, Storm G, Hennink WE, Kok RJ,. Drug targeting to the kidney: Advances in the active targeting of therapeutics to proximal tubular cells. Adv Drug Deliv Rev 2010; 62: 1344-1357.